KLOW is a lyophilized research blend that puts four peptides in a single vial: GHK-Cu, BPC-157, TB-500 (thymosin β4) and KPV. Each of the four has its own published research history, studied separately in cell culture and animal models. The blend itself is a lab formulation, not a compound with its own literature. This overview explains what each component is, what the separate research covers, and where the evidence for using them together stops.
At a glance
- Type: Four-peptide lyophilized research blend
- Components: GHK-Cu, BPC-157, TB-500 (thymosin β4) and KPV
- Total per vial: 80 mg; the amount of each component is listed on the batch COA
- Research basis: Each component has its own preclinical literature; no peer-reviewed study has examined this four-peptide combination
- Regulatory status: None of the four is an FDA-approved drug; BPC-157 and TB-500 are on the WADA Prohibited List
Why laboratories study these peptides side by side
The four components come from very different places. GHK-Cu is a copper complex of a tripeptide found in human plasma. BPC-157 is a synthetic 15-residue peptide derived from a gastric protein sequence. TB-500 refers to thymosin β4, an actin-binding protein present in most cell types. KPV is a three-residue fragment of α-melanocyte-stimulating hormone.
What links them is the kind of model they turn up in. Their separate literatures overlap around fibroblast and matrix biology, cell migration, vascular growth, tendon and wound models, and inflammation signaling. Groups working in those areas often compare them, and a combined vial lets a lab work from a single lot with a single certificate of analysis. KLOW contains the same three peptides as the GLOW blend and adds KPV, the component focused on inflammation signaling.
The four components
GHK-Cu
GHK-Cu pairs the tripeptide Gly-His-Lys with a copper(II) ion. The peptide was identified in human plasma in 1973 (Pickart and Thaler, 1973), and later work showed the copper complex stimulating collagen synthesis in fibroblast cultures (Maquart et al., 1988). Research covers copper coordination chemistry, fibroblast and matrix biology, and gene-expression analyses. Read the full GHK-Cu research overview.
BPC-157
BPC-157 is a synthetic pentadecapeptide developed and characterized by Predrag Sikiric’s group at the University of Zagreb. Rat and cell studies report effects on tendon fibroblast outgrowth, survival and migration (Chang et al., 2011), and a body of work examines its interaction with blood vessels (Seiwerth et al., 2014). Read the full BPC-157 research overview.
TB-500 (thymosin β4)
Thymosin β4 is a 43-residue protein best known for binding and sequestering actin monomers (Safer et al., 1991). In culture it promoted directional migration of endothelial cells (Malinda et al., 1997), and it has since been studied in cardiac, dermal and tendon injury models. Read the full TB-500 research overview.
KPV
KPV is the Lys-Pro-Val tripeptide from the C-terminal end of α-MSH. In intestinal epithelial cells it is taken up through the PepT1 transporter and reduced inflammatory signaling, with protective effects in mouse colitis models (Dalmasso et al., 2008; Kannengiesser et al., 2008). Read the full KPV research overview.
Is there research on the combination?
Very little. A 2026 rat Achilles tendon study compared BPC-157, TB-500 and the two given together, using histopathology and biomechanical load testing, and its authors described the results as exploratory (Biçer et al., 2026). We are not aware of any published study that tests GHK-Cu, BPC-157, TB-500 and KPV together, or that establishes how the four interact in one preparation.
What the evidence does not show
- The research on each component comes from cell culture and animal models. It does not establish any effect in humans.
- Findings for a single peptide cannot be assumed to hold when it is combined with others; the components could interact in ways no study has measured.
- No published work has examined this four-peptide blend as a whole.
- Several of the literatures come from a small number of research groups, and some findings have not been independently replicated.
Regulatory status
None of the four components is approved by the FDA as a drug. BPC-157 has been on the WADA Prohibited List under S0 since 2022, and thymosin β4 and its derivatives fall under WADA S2. The KLOW blend sold by Rogue Compounds is a research reagent for laboratory use only. It is not for human consumption.
Handling and storage in the lab
Lyophilized KLOW should be kept sealed and refrigerated at 2–8°C (36–46°F), protected from light.
Sourcing and documentation
Rogue Compounds has KLOW made in small batches. Every vial carries a batch number and a QR code that opens the independent U.S. testing lab’s own report for that batch, and the same batch COA, including the amount of each component, is on the product page and in the COA Library.
References
- Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85-87. PMID 4349963
- Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-346. PMID 3169264
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PMID 21030672
- Seiwerth S, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014;20(7):1121-1125. PMID 23782145
- Safer D, et al. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-4032. PMID 1999398
- Malinda KM, et al. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474-481. PMID 9194528
- Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. PMID 42542926
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID 18061177
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. PMID 18092346